1
09月
Qidu Pharma’s Qigejia®—Saxagliptin and Metformin Hydrochloride Extended-Release Tablets (I) was approved for marketingOn August 19, Qidu Pharma’s compound preparation for type 2 diabetes—Saxagliptin and Metformin Hydrochloride Extended-Release Tablets (I) (brand name: Qigejia®)—was officially approved by the National
4
08月
China 's pharmaceutical industry main business income top 100 list released - Qidu Pharma ranked 83rdFrom July 5 to 7, the 42nd National Pharmaceutical Industry Information Annual Conference and the 2025 Beijing·Changping Life Science Forum, organized by the China Pharmaceutical Information Center, w
4
08月
Three new products of Qidu Pharma were approved for marketing on the same dayOn July 30, three groundbreaking self-developed products by Qidu Pharma——— Qiliwei®-Peramivir Sodium Chloride Injection, Gaiweian®-Calcium Chloride Injection, and Kangyuxin®-Isavuconazole Sulfate for
4
08月
The intelligent production project of Qidu Pharma 's annual output of 10 billion tablets of oral preparations passed the GMP on-site inspFrom July 21 to 25, a team of nine experts from Shandong Provincial Drug Administration conducted comprehensive inspections at Qidu Pharma's newly constructed intelligent production project for annual
4
08月
Metoclopramide injection and API of Qidu Pharma were approved for marketingOn July 28, Qidu Pharma's Anweitong ®-Methoclopramide Hydrochloride Injection passed the consistency evaluation by China's National Medical Products Administration. The formulation contains 2ml of 10m